Exelixis Inc. Aktie
37,35 €
Deine Einschätzung
Exelixis Inc. Aktie
Die Analyse-Plattform Leeway untersucht mit KI-unterstützten Algorithmen aussagekräftige Zusammenhänge am Aktienmarkt. Anhand von vielen Millionen Datenpunkten finden die Algorithmen die Kennzahlen und Bewegungen, die nachweisbare Auswirkungen haben und Vorteile schaffen.
Was spricht für und gegen Exelixis Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Exelixis Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | -1,91 % | 9,30 % | 5,58 % | 89,28 % | 20,62 % | 87,21 % | 88,87 % |
| Ironwood Pharmaceuticals | 1,68 % | 7,08 % | 26,57 % | -89,75 % | -85,60 % | -94,27 % | -93,01 % |
| Arrowhead Pharmaceuticals Inc. | -2,26 % | -0,63 % | 0,68 % | -47,16 % | -27,49 % | -58,74 % | -62,03 % |
| Novocure Ltd | 0,24 % | -5,58 % | -10,30 % | -16,09 % | -49,76 % | -79,57 % | -72,27 % |
Kommentare
News
2 Top Stocks to Buy With Less Than $100
When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that
Why Exelixis Stock Is Skyrocketing Today
Shares of Exelixis (NASDAQ: EXEL) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. The huge gain came after the drugmaker announced its 2025 first-quarter results Tuesday evening.
Exelixis Stock: Executives Sell as Shares Near Peak
Exelixis is experiencing significant insider selling activity while its stock trades near its 52-week high of €37.64. Three high-ranking executives recently reduced their holdings in substantial
